MSCL (MSCL) News
Follow MSCL (MSCL) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 8 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Satellos Bioscience Inc. (MSCL) Completes Phase 2 DMD Trial Enrollment; Topline Data Slips to Q1 2027
Satellos completed enrollment in BASECAMP, its Phase 2 trial of forazapadin in ambulatory boys with DMD, and now expects to share topline data in Q1 2027 after adjusting the prior plan to compile a more complete dataset.
NEWS | Sep 30, 2026, 11:08 AM UTC
L
Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy
Data from BASECAMP expected in Q1 2027TORONTO, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to treat
NEWS | Sep 30, 2026, 11:08 AM UTC
L
Satellos Bioscience Inc. (MSCL) Gets FDA IND OK For FSHD; Up To $5M Funding
Satellos received FDA clearance of its IND for forazapadin in FSHD and secured up to $5M in non-dilutive milestone funding from FSHD Canada. A Phase 2 study is expected to start in Q4 2026.Material DetailsContext by AI A
REGULATION | Sep 24, 2026, 11:02 AM UTC
L
Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development
TORONTO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage drug development company developing potentially life-improving medicines to treat degenerative muscle disea
REGULATION | Sep 24, 2026, 11:01 AM UTC
L
MSCL: Phase II trials of forazapadin show early promise in muscle regeneration, with pivotal data expected soon
The conference highlighted forazapadin's novel approach to muscle regeneration in Duchenne and FSHD, with two phase II trials set to deliver key data by early next year. Early results show functional and biomarker improv
EQUITY | Sep 09, 2026, 09:33 PM UTC
L
MSCL: Phase II data for forazapadin in DMD and FSHD expected soon, with early signs of clinical benefit
Forazapadin, a novel therapy targeting muscle stem cell regeneration, is advancing through two phase II trials in DMD, with key data expected by year-end. Early results show improved muscle strength and fat fraction, and
EQUITY | Sep 09, 2026, 08:57 PM UTC
L
Satellos’ lead drug candidate SAT-3247 gets INN “forazapadin”
Satellos Bioscience announced assignment of the International Nonproprietary Name “forazapadin” for its lead drug candidate, SAT-3247.
EQUITY | Sep 09, 2026, 11:03 AM UTC
L
Satellos management to participate in upcoming investor conferences
Satellos Bioscience Inc. said management will participate in upcoming investor conferences, according to a Globe Newswire announcement.
EQUITY | Sep 01, 2026, 11:07 AM UTC